The metabolic syndrome following kidney transplantation

Kidney International

Volumn 78, Issue SUPPL. 118, 2010, Pages

  Goldsmith, David ^a   Pietrangeli, Carolynn E ^b  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^b CTI Clinical Trial and Consulting Services   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; EZETIMIBE; FLUINDOSTATIN; GLIPIZIDE; GLUCOSE; LIPID; LISINOPRIL; LOSARTAN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NIFEDIPINE; PREDNISONE; RAPAMYCIN; TACROLIMUS;

ABDOMINAL OBESITY; BLOOD PRESSURE; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIALYSIS; DISEASE EXACERBATION; DRUG DOSE INCREASE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GLUCOSE BLOOD LEVEL; GRAFT RECIPIENT; HUMAN; HYPERGLYCEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INSULIN RESISTANCE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIFESTYLE MODIFICATION; LIPID BLOOD LEVEL; LIPID METABOLISM; METABOLIC SYNDROME X; PATHOPHYSIOLOGY; POLYPHARMACY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; TREATMENT DURATION; WEIGHT GAIN;

HUMANS; INCIDENCE; KIDNEY TRANSPLANTATION; MALE; METABOLIC SYNDROME X; POSTOPERATIVE COMPLICATIONS; PREVALENCE;

EID: 77955626158     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2010.210     Document Type: Review

References (64)

1. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-1607.
2. Huang PL. A comprehensive definition for metabolic syndrome. Dis Model Mech 2009; 2: 231-237.
3. Grundy SM. Metabolic syndrome: connecting and reconciling cardiovascular and diabetes worlds. J Am Coll Cardiol 2006; 47: 1093-1100.
4. Grundy SM, Brewer Jr HB, Cleeman JI et al. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004; 109: 433-438.
5. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome\a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med 2006; 23: 469-480.
6. Natali A, Pucci G, Boldrini B et al. Metabolic syndrome: at the crossroads of cardiorenal risk. J Nephrol 2009; 22: 29-38.
7. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome\a new worldwide definition. Lancet 2005; 366: 1059-1062.
8. Grundy SM. Metabolic syndrome pandemic. Arterioscler Thromb Vasc Biol 2008; 28: 629-636.
9. Kahn R, Buse J, Ferrannini E et al. The metabolic syndrome: time for a critical appraisal. Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2005; 48: 1684-1699. (Pubitemid 41317821)
10. Hillier TA, Rousseau A, Lange C et al. Practical way to assess metabolic syndrome using a continuous score obtained from principal components analysis. Diabetologia 2006; 49: 1528-1535.
11. Schillaci G, Pirro M, Vaudo G et al. Prognostic value of the metabolic syndrome in essential hypertension. J Am Coll Cardiol 2004; 43: 1817-1822.
12. Malik S, Wong ND, Franklin SS et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 2004; 110: 1245-1250.
13. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002; 287: 356-359.
14. Ford ES, Giles WH, Mokdad AH. Increasing prevalence of the metabolic syndrome among us Adults. Diabetes Care 2004; 27: 2444-2449.
15. Pierdomenico SD, Lapenna D, Di Tommaso R et al. Prognostic relevance of metabolic syndrome in hypertensive patients at low-to-medium risk. Am J Hypertens 2007; 20: 1291-1296.
16. Andreadis EA, Tsourous GI, Tzavara CK et al. Metabolic syndrome and incident cardiovascular morbidity and mortality in a Mediterranean hypertensive population. Am J Hypertens 2007; 20: 558-564.
17. Girman CJ, Rhodes T, Mercuri M et al. The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Am J Cardiol 2004; 93: 136-141.
18. McNeill AM, Rosamond WD, Girman CJ et al. The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study. Diabetes Care 2005; 28: 385-390.
19. Gami AS, Witt BJ, Howard DE et al. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol 2007; 49: 403-414.
20. Trujillo ME, Scherer PE. Adiponectin\journey from an adipocyte secretory protein to biomarker of the metabolic syndrome. J Intern Med 2005; 257: 167-175.
21. Becker B, Kronenberg F, Kielstein JT et al. Renal insulin resistance syndrome, adiponectin and cardiovascular events in patients with kidney disease: the mild and moderate kidney disease study. J Am Soc Nephrol 2005; 16: 1091-1098.
22. Hjelmesaeth J, Flyvbjerg A, Jenssen T et al. Hypoadiponectinemia is associated with insulin resistance and glucose intolerance after renal transplantation: impact of immunosuppressive and antihypertensive drug therapy. Clin J Am Soc Nephrol 2006; 1: 575-582.
23. Leoncini G, Ratto E, Viazzi F et al. Metabolic syndrome is associated with early signs of organ damage in nondiabetic, hypertensive patients. J Intern Med 2005; 257: 454-460.
24. Schillaci G, Pirro M, Pucci G et al. Different impact of the metabolic syndrome on left ventricular structure and function in hypertensive men and women. Hypertension 2006; 47: 881-886.
25. Scuteri A, Najjar SS, Muller DC et al. Metabolic syndrome amplifies the age-associated increases in vascular thickness and stiffness. J Am Coll Cardiol 2004; 43: 1388-1395.
26. Schillaci G, Pirro M, Vaudo G et al. Metabolic syndrome is associated with aortic stiffness in untreated essential hypertension. Hypertension 2005; 45: 1078-1082.
27. Bonnet F, Marre M, Halimi JM et al. Waist circumference and the metabolic syndrome predict the development of elevated albuminuria in non-diabetic subjects: the DESIR Study. J Hypertens 2006; 24: 1157-1163.
28. Weir MR. Microalbuminuria and cardiovascular disease. Clin J Am Soc Nephrol 2007; 2: 581-590.
29. Heinig M, Johnson RJ. Role of uric acid in hypertension, renal disease, and metabolic syndrome. Cleve Clin J Med 2006; 73: 1059-1064.
30. Ford ES, Li C, Cook S et al. Serum concentrations of uric acid and the metabolic syndrome among US children and adolescents. Circulation 2007; 115: 2526-2532.
31. Erdogan D, Gullu H, Caliskan M et al. Relationship of serum uric acid to measures of endothelial function and atherosclerosis in healthy adults. Int J Clin Pract 2005; 59: 1276-1282.
32. Zoccali C, Maio R, Mallamaci F et al. Uric acid and endothelial dysfunction in essential hypertension. J Am Soc Nephrol 2006; 17: 1466-1471.
33. Kang DH, Park SK, Lee IK et al. Uric acid-induced C-reactive protein expression: implication on cell proliferation and nitric oxide production of human vascular cells. J Am Soc Nephrol 2005; 16: 3553-3562.
34. Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med 2008; 359: 1811-1821.
35. Marcen R. Immunosuppressive drugs in kidney transplantation: impact on patient survival, and incidence of cardiovascular disease, malignancy and infection. Drugs 2009; 69: 2227-2243.
36. Nankivell BJ, Borrows RJ, Fung CL et al. Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology. Transplantation 2004; 78: 557-565.
37. Hardinger KL, Koch MJ, Brennan DC. Current and future immunosuppressive strategies in renal transplantation. Pharmacotherapy 2004; 24: 1159-1176.
38. Citterio F. Steroid side effects and their impact on transplantation outcome. Transplantation 2001; 72(12 Suppl): S75-S80.
39. Knight SR, Morris PJ. Steroid avoidance or withdrawal after renal transplantation increases the risk of acute rejection but decreases cardiovascular risk. A meta-analysis. Transplantation 2010; 89: 1-14.
40. Wiseman AC. Polyomavirus nephropathy: a current perspective and clinical considerations. Am J Kidney Dis 2009; 54: 131-142.
41. Mulay AV, Cockfield S, Stryker R et al. Conversion from calcineurin inhibitors to sirolimus for chronic renal allograft dysfunction: a systematic review of the evidence. Transplantation 2006; 82: 1153-1162.
42. Diekmann F, Budde K, Slowinski T et al. Conversion to sirolimus for chronic allograft dysfunction: long-term results confirm predictive value of proteinuria. Transpl Int 2008; 21: 152-155.
43. Schena FP, Pascoe MD, Alberu J et al. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation 2009; 87: 233-242.
44. Franz S, Regeniter A, Hopfer H et al. Tubular toxicity in sirolimus-and cyclosporine-based transplant immunosuppression strategies: an ancillary study from a randomized controlled trial. Am J Kidney Dis 2010; 55: 335-343.
45. Pescovitz MD, Nezakatgoo N, Lorber MI et al. Prospective observational study of sirolimus as primary immunosuppression after renal transplantation. Transplantation 2009; 88: 1010-1018.
46. Ekberg H, Bernasconi C, Noldeke J et al. Cyclosporine, tacrolimus and sirolimus retain their distinct toxicity profiles despite low doses in the Symphony study. Nephrol Dial Transplant 2010; 25: 2004-2010.
47. Mulay AV, Hussain N, Fergusson D et al. Calcineurin inhibitor withdrawal from sirolimus-based therapy in kidney transplantation: a systematic review of randomized trials. Am J Transplant 2005; 5: 1748-1756.
48. Sofroniadou S, Kassimatis T, Goldsmith D. Anaemia, microcytosis and sirolimus\is iron the missing link? Nephrol Dial Transplant 2010; 25: 1667-1675.
49. Johnston O, Rose CL, Webster AC et al. Sirolimus is associated with new-onset diabetes in kidney transplant recipients. J Am Soc Nephrol 2008; 19: 1411-1418.
50. De Vries AP, Bakker SJ, van Son WJ et al. Metabolic syndrome is associated with impaired long-term renal allograft function; not all component criteria contribute equally. Am J Transplant 2004; 4: 1675-1683.
51. Veldt BJ, Poterucha JJ, Watt KD et al. Insulin resistance, serum adipokines and risk of fibrosis progression in patients transplanted for hepatitis C. Am J Transplant 2009; 9: 1406-1413.
52. Kliem V, Michel U, Burg M et al. Geographical prevalence, risk factors and impact of hepatitis B and C after renal transplantation. Clin Nephrol 2009; 71: 423-429.
53. Bloom RD, Lake JR. Emerging issues in hepatitis C virus-positive liver and kidney transplant recipients. Am J Transplant 2006; 6: 2232-2237.
54. Kasiske BL, Snyder JJ, Gilbertson D et al. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 2003; 3: 178-185.
55. Dooldeniya MD, Dupont PJ, He X et al. Renal transplantation in Indo-Asian patients in the UK. Am J Transplant 2006; 6: 761-769.
56. Van Laecke S, Van Biesen W, Verbeke F et al. Posttransplantation hypomagnesemia and its relation with immunosuppression as predictors of new-onset diabetes after transplantation. Am J Transplant 2009; 9, 2140-2149
57. Kang ES, Kim MS, Kim YS et al. A variant of the transcription factor 7-like 2 (TCF7L2) gene and the risk of posttransplantation diabetes mellitus in renal allograft recipients. Diabetes Care 2008; 31: 63-68.
58. Chakkera HA, Hanson RL, Raza SM et al. Pilot study: association of traditional and genetic risk factors and new-onset diabetes mellitus following kidney transplantation. Transplant Proc 2009; 41: 4172-4177.
59. Kang ES, Kim MS, Kim YS et al. A polymorphism in the zinc transporter gene SLC30A8 confers resistance against posttransplantation diabetes mellitus in renal allograft recipients. Diabetes 2008; 57: 1043-1047.
60. Luan FL, Stuckey LJ, Ojo AO. Abnormal glucose metabolism and metabolic syndrome in non-diabetic kidney transplant recipients early after transplantation. Transplantation 2010; 89: 1034-1039.
61. Sharif A, Ravindran V, Dunseath G et al. Comparison of rival metabolic syndrome classifications against pathophysiological markers in renal transplant recipients. Transplantation 2010; 89: 347-352.
62. Sharif A. Metabolic syndrome and solid-organ transplantation. Am J Transplant 2010; 10: 12-17.
63. Sarnak MJ, Levey AS, Schoolwerth AC et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003; 108: 2154-2169.
64. Meier-Kriesche HU, Baliga R, Kaplan B. Decreased renal function is a strong risk factor for cardiovascular death after renal transplantation. Transplantation 2003; 75: 1291-1295.